Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28606141 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL27278368 | 0.85 | AXL (0.42) | SMN1; SMN2CYP2C19NPC1RAB9ACYP2C9 | |
| SCHEMBL27059333 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL31330743 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL30066280 | 0.79 | KDM5A (0.44) | SMN1; SMN2CYP2C19CYP2C9CYP3A4GPR119 | |
| SCHEMBL18368416 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL30891597 | 0.79 | PREP (0.47) | SMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL28978073 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL19732305 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B | |
| SCHEMBL15018080 | 0.78 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP2C19NPC1RAB9AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| CN-113993861-B | Phenyl ethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
| CN-113993861-A | Phenylethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives and compositions and methods thereof | 凌科药业(杭州)有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK3, JAK1, JAK2 | SMN1; SMN2 2903/4885CYP2C19 95/4885NPC1 2216/4885 |
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | SMN1; SMN2 2935/4885CYP2C19 97/4885NPC1 2143/4885 |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | SMN1; SMN2 3124/4885CYP2C19 174/4885NPC1 2368/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | SMN1; SMN2 3124/4885CYP2C19 174/4885NPC1 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.